Beta Blockade in the Post‐Myocardial Infarction Setting: Pharmacologic Rationale and Clinical Evidence
| Autor: | Randall E. Williams |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Adrenergic beta-Antagonists Myocardial Infarction Infarction Post myocardial infarction Ventricular Dysfunction Left Risk Factors Internal medicine medicine Humans cardiovascular diseases Myocardial infarction Beta (finance) Contraindication Randomized Controlled Trials as Topic Heart Failure Evidence-Based Medicine business.industry Public Health Environmental and Occupational Health Arrhythmias Cardiac medicine.disease Blockade Clinical evidence Heart failure cardiovascular system Cardiology Cardiology and Cardiovascular Medicine business |
| Zdroj: | Preventive Cardiology. 9:96-101 |
| ISSN: | 1751-7141 1520-037X |
| DOI: | 10.1111/j.1520-037x.2006.04690.x |
| Popis: | The use of beta blockers reduces the risk of arrhythmias, reinfarction, and heart failure in both the immediate and long-term periods after a myocardial infarction. Every patient should be prescribed a beta blocker after a myocardial infarction unless there is a strong contraindication to therapy. Despite compelling evidence and recommendations, beta blockers remain an underutilized therapy in the post-myocardial infarction period. Evidence-based recommendations for the choice of agent and the practical implementation of beta blockers are reviewed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text